Table 2.

IC50 of Daunomycin (DNM) in the presence of buthionine sulfoximine (BSO) and/or verapamil (VRP)

Drug combination	BHK/CFTR (nM)b	BHK/MRP1 (nM)	RFa	H69 (nM)	H69AR (nM)	RFa
DNM	1.92 ± 0.08	13.92 ±0.76	7.25	85.32 ± 6.95	1362.23 ± 262.13	15.97
DNM + 10 µM BSO	2.12 ±0.29	4.42 ±0.15	2.08	92.26 ± 1.52	133.82 ± 3.53	1.45
DNM + 0.1 µM VRP	2.37 ±0.57	16.90 ± 4.69	7.19	94.83 ± 4.78	1216.15 ± 63.85	12.82
DNM + 1µM VRP	2.50 ± 0.07	4.81 ±0.10	1.92	82.85 ±12.22	477.35 ± 11.21	5.76
DNM + 10 µM BSO + 0.1 µM VRP	2.12 ±0.32	3.69 ±0.31	1.74	92.84 ± 2.43	143.51 ± 15.86	1.55
DNM + 10 µM BSO + 1 µM VRP	2.05 ± 0.08	0.03 ± 0.00	0.01	87.82 ± 2.52	147.11 ± 28.53	1.68
DNM + 10 µM VRP				81.83 ± 4.83	182.70 ± 4.70	2.23
DNM + 10 µM VRP				76.73 ± 5.11	34.36 ± 5.61	0.45

^aRF = Resistance Factor

^bThe experiments were performed in triplicate and repeated twice.